The complex role of AR signaling after cytotoxic insult - Implications for cell cycle based chemotherapeutics

被引:25
作者
Comstock, Clay E. S.
Knudsen, Karen E.
机构
[1] Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH USA
[2] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH USA
[3] Univ Cincinnati, Coll Med, Barrett Canc Ctr, Cincinnati, OH USA
关键词
prostate cancer; androgen receptor; pre-clinical; taxane; docetaxel; flavopiridol;
D O I
10.4161/cc.6.11.4353
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Prostatic adenocarcinomas are dependent on androgen receptor (AR) signaling for growth and progression, in part through the ability of AR to induce G(1)-S phase cell cycle transition. Hormonal therapies that inhibit AR activity are the first line of intervention for disseminated disease, and are initially quite effective; however, recurrent, incurable tumors ultimately arise with restored AR function. Given the importance of AR in governing the potentiation of this tumor type, there has been a dedicated interest in dissecting the mechanisms by which AR promotes prostate cancer proliferation and survival. Recent studies have challenged the utility of manipulating AR activity to enhance cell death in combination with genotoxic insult. Herein, the role of AR in controlling cell cycle progres sion and paradoxical roles of AR in survival signals are considered, as are the potential implications of these findings for chemotherapeutic response. Although there is much to be resolved, the present data suggest that knowledge of AR action in promoting cellular proliferation can be utilized for the design of coordinate strategies that maximize cell death in response to cytotoxic chemotherapeutics.
引用
收藏
页码:1307 / 1313
页数:7
相关论文
共 93 条
[1]   Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence [J].
Agus, DB ;
Cordon-Cardo, C ;
Fox, W ;
Drobnjak, M ;
Koff, A ;
Golde, DW ;
Scher, HI .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) :1869-1876
[2]   Targeted therapies for prostate cancer [J].
Asatiani, E ;
Gelmann, EP .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (02) :283-298
[3]  
BERCHEM GJ, 1995, CANCER RES, V55, P735
[4]   Prolonged mitosis versus tetraploid checkpoint - How p53 measures the duration of mitosis [J].
Blagosklonny, MV .
CELL CYCLE, 2006, 5 (09) :971-975
[5]   Flavopiridol inversely affects p21WAF1/CIP1 and p53 and protects p21-sensitive cells from paclitaxel [J].
Blagosklonny, MV ;
Darzynkiewicz, Z ;
Figg, WD .
CANCER BIOLOGY & THERAPY, 2002, 1 (04) :420-425
[6]   Dihydrotestosterone enhances transforming growth factor-ß-induced apoptosis in hormone-sensitive prostate cancer cells [J].
Bruckheimer, EM ;
Kyprianou, N .
ENDOCRINOLOGY, 2001, 142 (06) :2419-2426
[7]   Cell cycle molecular targets in novel anticancer drug discovery [J].
Buolamwini, JK .
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04) :379-392
[8]   Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation [J].
Burd, CJ ;
Petre, CE ;
Morey, LM ;
Wang, Y ;
Revelo, MP ;
Haiman, CA ;
Lu, S ;
Fenoglio-Preiser, CM ;
Li, JW ;
Knudsen, ES ;
Wong, JM ;
Knudsen, KE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2190-2195
[9]  
Camphausen K, 2004, MOL CANCER THER, V3, P409
[10]   The PSA era is not over for prostate cancer [J].
Catalona, WJ ;
Loeb, S .
EUROPEAN UROLOGY, 2005, 48 (04) :541-545